Search Results - "PAMBID, Mary Rose"

Concise Review: Bullseye: Targeting Cancer Stem Cells to Improve the Treatment of Gliomas by Repurposing Disulfiram by Triscott, Joanna, Rose Pambid, Mary, Dunn, Sandra E.

“…Cancer stem cells (CSCs) are thought to be at the root of cancer recurrence because they resist conventional therapies and subsequently reinitiate tumor cell…”
Get full text

Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC) by Dunn, Sandra E., Jayanthan, Aarthi, Huynh, My-my, Flahive, Erik, Pambid, Mary Rose, Dorr, Andrew, Los, Gerrit

“…In an effort to find novel drug targets for triple negative breast cancer (TNBC), Phoenix Molecular Designs (PhoenixMD) has developed PMD-026, the first orally…”
Get full text

Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients by Beeram, Murali, Wang, Judy S., Chalasani, Pavani, Mina, Lida, Patnaik, Amita, Pambid, Mary Rose, Jayanthan, Aarthi, Huynh, My-my, Los, Gerrit, Dunn, Sandra E., Dorr, F. Andrew

“…Background: Metastatic breast cancer (mBC) remains an aggressive disease with limited durable treatment options; the worst prognosis among the breast cancer…”
Get full text

YB‐1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal‐Like Breast Cancer by Davies, Alastair H., Reipas, Kristen M., Pambid, Mary Rose, Berns, Rachel, Stratford, Anna L., Fotovati, Abbas, Firmino, Natalie, Astanehe, Arezoo, Hu, Kaiji, Maxwell, Christopher, Mills, Gordon B., Dunn, Sandra E.

“…There is growing evidence that cancer‐initiation could result from epigenetic changes. Y‐box binding protein‐1 (YB‐1) is a transcription/translation factor…”
Get full text

Abstract 1038: PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models by Jayanthan, Aarthi, Huynh, My-my, Lee, Jangsoon, Los, Gerrit, Yue, Lambert, Pambid, Mary Rose, Ueno, Naoto T., Dunn, Sandra E.

“…PMD-026 is a first in class, reversible, oral small molecule inhibitor of p90 ribosomal S6 kinase (RSK), a kinase family activated by the MAPK and PDK-1…”
Get full text

The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials by Huynh, My-My, Pambid, Mary Rose, Jayanthan, Aarthi, Dorr, Andrew, Los, Gerrit, Dunn, Sandra E

“…Triple negative breast cancer (TNBC) was once thought to be an insurmountable disease marked by a lack of targeted treatments. However, we are now witnessing…”
Get more information

RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer by Huynh, My-My, Jayanthan, Aarthi, Pambid, Mary Rose, Los, Gerrit, Dunn, Sandra E

Get more information

First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer by Beeram, Muralidhar, Wang, Judy Sing-Zan, Mina, Lida A., Patnaik, Amita, Pambid, Mary Rose, Jayanthan, Aarthi, Huynh, My-my, Dunn, Sandra Elaine, Los, Gerrit, Dorr, Andrew

“…Abstract only TPS1110 Background: Metastatic triple negative breast cancer (mTNBC) has a poor prognosis with limited durable treatment options. RSK (P90…”
Get full text

First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer by Beeram, Muralidhar, Chalasani, Pavani, Wang, Judy S., Mina, Lida A., Shatsky, Rebecca Arielle, Trivedi, Meghna S., Wesolowski, Robert, Hurvitz, Sara A., Han, Hyo S., Patnaik, Amita, Pambid, Mary Rose, Jayanthan, Aarthi, Huynh, My-my, Los, Gerrit, Dunn, Sandra Elaine, Dorr, Andrew

“…Abstract only e13043 Background: P90 ribosomal S6 kinase (RSK) is an actionable molecular target against metastatic triple negative breast cancer (mTNBC). RSK…”
Get full text

Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children by TRISCOTT, Joanna, LEE, Cathy, HAWKINS, Cynthia, RAMASWAMY, Vijay, BOUFFET, Eric, TAYLOR, Michael D, SINGHAL, Ash, HUKIN, Juliette, RASSEKH, Rod, YIP, Stephen, NORTHCOTT, Paul, SINGH, Sheila K, FOSTER, Colleen, DUNHAM, Christopher, DUNN, Sandra E, MANORANJAN, Branavan, PAMBID, Mary Rose, BERNS, Rachel, FOTOVATI, Abbas, VENUGOPAL, Chitra, O'HALLORAN, Katrina, NARENDRAN, Aru

“…Medulloblastoma is the most common malignant brain tumor in children. This disease is heterogeneous and is composed of four subtypes of medulloblastoma [WNT,…”
Get full text

Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients by Beeram, Muralidhar, Wang, Judy S., Mina, Lida A., Chalasani, Pavani, Shatsky, Rebecca A., Wesolowski, Robert, Hurvitz, Sara A., Trivedi, Meghna S., Han, Hyo S., Patnaik, Amita, Huynh, My-my, Jayanthan, Aarthi, Pambid, Mary Rose, Yue, Lambert, Los, Gerrit, Dunn, Sandra E., Dorr, Andrew

“…Background: Durably effective therapeutic options remain elusive for metastatic triple negative breast cancer (mTNBC) patients. RSK is a novel target kinase…”
Get full text

Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma by Pambid, Mary Rose, Berns, Rachel, Adomat, Hans H., Hu, Kaiji, Triscott, Joanna, Maurer, Norbert, Zisman, Natalia, Ramaswamy, Vijay, Hawkins, Cynthia E., Taylor, Michael D., Dunham, Christopher, Guns, Emma, Dunn, Sandra E.

“…Background Molecular subtyping has allowed for the beginning of personalized treatment in children suffering from medulloblastoma (MB). However, resistance…”
Get full text

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification by Davies, A H, Barrett, I, Pambid, M R, Hu, K, Stratford, A L, Freeman, S, Berquin, I M, Pelech, S, Hieter, P, Maxwell, C, Dunn, S E

“…Y-box binding protein-1 (YB-1) expression in the mammary gland promotes breast carcinoma that demonstrates a high degree of genomic instability. In the present…”
Get full text